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50.1 Inﬂammatory bowel diseases
Inﬂammatory bowel diseases (IBDs) are chronic relapsing dis­
eases associated with debilitating symptoms and leading to
progressive intestinal tissue damage and disability (Figure 50.1).
Crohn’s disease (CD) can affect any part of the gastrointestinal
tract, and lesions are often segmental and transmural. The
disease was named after gastroenterologist Dr Burrill Bernard
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Crohn, who, in 1932, together with two other colleagues at
Mount Sinai Hospital in New York, described a series of patients
with inﬂammation of the terminal ileum of the small intestine,
the area most commonly affected by the illness. Active CD is
characterized by focal inﬂammation with granulomas and for­
mation of ﬁstula tracts or abscesses, and chronic lesions include
ﬁbrosis and stricture of the bowel (Figure 50.2).
In ulcerative colitis (UC),mucosal inﬂammation is continuous
and limited to the mucosa and superﬁcial submucosa. Lesions
can affect the rectum and to a variable extent the colon, without
granulomas or ﬁstulas. The age of onset of IBD ismost frequently
in late adolescence or early adulthood, and the disease is equally
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Figure 50.1 Diagram of the human intestine. Drawn by Duncan Lock and
released into the Public Domain. Source: http://commons.wikimedia.org/
wiki/File:Intestine-diagram.svg#mediaviewer/File:Intestine-diagram.svg.
distributed between the sexes. The incidence and prevalence are
stable in high-incidence areas (northern Europe and North
America), and rising in low-incidence areas (southern Europe,
Asia, and most developing countries) [1,2].
Symptoms of CD are heterogeneous, but commonly include
chronic diarrhea, abdominal pain, weight loss, anorexia, and/or
fever. Rectal bleeding occurs commonly in UC, while perianal
ﬁssures, ﬁstulas, or abscesses can occur in CD. Extraintestinal
features can be related to extraintestinal inﬂammation, such as
joint inﬂammation (spondyloarthritis, peripheral arthritis),
Figure 50.2 A portion of resected jejunum showing the typical cobble­
stone appearance of CD affecting the jejunum. Source: http://commons
.wikimedia.org/wiki/File:Crohn_Jejunum.PNG#mediaviewer/File:
Crohn_Jejunum.PNG.
Figure 50.3 Erythema nodosum is an inﬂammatory condition
characterized by inﬂammation of the fat cells under the skin, resulting in
tender red nodules or lumps. It can be caused by a variety of conditions
and typically resolves spontaneously within 3–6 weeks. The commonest
distribution of erythema nodosum is on the shins – the anterior aspect of
the lower legs. Source: 1905, William Wood and Company.
cutaneous manifestations – erythema nodosum (Figure 50.3),
pyoderma gangrenosum (Figure 50.4) – ocular inﬂammation
(uveitis, episcleritis, sclero-conjunctivitis), and primary scleros­
ing cholangitis, or are consequences of malabsorption (choleli­
thiasis, nephrolithiasis, and osteoporosis) [3].
The diagnosis is based on clinical evaluation and a combina­
tion of endoscopic, histological, radiological (computed tomog­
raphy scan, magnetic resonance imaging (MRI)), and/or
biochemical (C-reactive protein (CRP), full blood count, and
fecal calprotectin) investigations. The histologic diagnosis is
based on the presence of discontinuous chronic inﬂammation,
focal crypt irregularity, and granulomas in CD [4].
50.2 Pathogenesis of inﬂammatory
bowel diseases
The etiology of IBD is multifactorial, polygenic [5], and environ­
mental [6] and includes an abnormal systemic and mucosal
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Figure 50.4 Pyoderma gangrenosum affecting the lower leg of a person
with CD. This is a condition that causes tissue to become necrotic,
resulting in deep ulcers that usually occur on the legs. Ulcers usually
initially look like small bug bites or papules and then progress to larger
ulcers. While the ulcers rarely lead to death, they can cause pain and
scarring. Although the etiology is not well understood, the disease is
thought to be due to immune system dysfunction, and particularly
abnormal functioning of neutrophils. The commonest diseases
associated with pyoderma gangrenosum are the IBDs (CD and UC),
followed by the arthritides such as rheumatoid arthritis, followed
by malignant hematological disorders. (See color plate section.)
Source: http://commons.wikimedia.org/wiki/File:Crohnie_Pyoderma_
gangrenosum.jpg#ﬁle.
immune response against intraluminal antigens, favored by
microbial factors [7] and alteration of the mucosal barrier [8].
A key role in the pathogenesis of IBD seems to be played by
enhanced proliferation and defective apoptosis of immune cells,
attributed to an imbalance of the antiapoptotic protein BCL-2
and the pro-apoptotic protein BAX [9,10]), as well as by proin­
ﬂammatory cytokines arising fromThelper cells (Th)1 andTh17
CD4T cell differentiation inCD, andTh2T cell differentiation in
UC [11–13]. The loss of balance between proliferation and
apoptosis is responsible for the presence of an abnormal popu­
lation of T cells with extended lifespan, which remains in the
mucosal compartment and secretes proinﬂammatory cytokines.
The result is an activation of other inﬂammatory cells, including
macrophages and B cells, and a recruitment of circulating
leukocytes into the gut through interactions between homing
receptors (e.g., α4β7 integrin) and addressins on vascular endo­
thelium, such as the mucosal vascular addressin cell adhesion
molecule (MAdCAM)-1 or the vascular cell adhesion molecule
(VCAM)-1.
In CD the initial phase of the inﬂammation seems to be
predominantly driven by a Th1 response. Interleukin (IL)-12,
a proinﬂammatory cytokine produced by dendritic cells
(DCs), promotes the conversion of T cells into Th1 cells,
secreting interferon (INF)-γ and tumor necrosis factor
(TNF)-α, two major actors in the induction and propagation
of inﬂammation [14–18]. In a later phase, the importance of
the Th17 response increases. Th17 cells are induced by IL-6
and transforming growth factor (TGF)-β, and secrete IL-17
and IL-22. IL-23, produced by DCs, interacts with Th17
cells and increases the secretion of IL-6 and IL-17 by T cells,
thus enhancing the inﬂammatory response [19–24]. This
overactive immune response can lead to the development
of mucosal lesions. Defective apoptosis also promotes
autoimmunity, by a reduced autoantibody clearance. Inter­
estingly, almost all drugs with clinical efﬁcacy, including
inﬂiximab [25], are able to induce apoptosis of immune cells
in vitro, while etanercept, an anti-TNF-fusion protein that
does not induce apoptosis of immune cells [26], is not
efﬁcacious in the treatment of CD [27]. Nevertheless, certo­
lizumab pegol, another anti-TNF agent, is unable to induce
cell apoptosis [28], and yet is effective for inducing and
maintaining remission in active CD [29,30]. Eventually,
chronic inﬂammation induces intestinal ﬁbroblasts to prolif­
erate and produce a greater amount of extracellular matrix,
resulting in local intestinal ﬁbrosis [31].
Endoscopic appearances are shown in Figure 50.5.
InUC, inﬂammation ismainly driven by IL-5 and IL-13, while
production of INF-γ is normal. The disease is qualiﬁed as “Th2­
like” given the normal production of IL-4, the most deﬁning Th2
cytokine [11]. A Th17 response may also play a role, but its
importance is probably lower than in CD.
Figure 50.5 (A) Normal ileum: the mucosa is homogeneously pink and
the villi are regular and well developed. (B) Crohn’s ileitis: diffuse
inﬂammation characterized by erythema and mucosal hemorrhage.
(C) Crohn’s ileitis: presence of erythema and ulcers; red dots indicate
mucosal hemorrhages. (D) Normal colon: colonic folds are present and
regular. The vascular pattern is also readily visible. (E, F) Crohn’s colitis:
presence of diffuse inﬂammation with erythema and superﬁcial ulcers.
(G) Healed colon. (See color plate section.)
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Table 50.1 The CDAI is a research tool used to quantify the symptoms of patients with CD.
Clinical or laboratory variable Weighting factor
Number of liquid or soft stools each day for 7 days ×2
Abdominal pain (graded from 0 to 3 on severity) each day for 7 days ×5
General wellbeing, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days ×7
Presence of complicationsa ×20
Taking Lomotil or opiates for diarrhea ×30
Presence of an abdominal mass (0 as none, 2 as questionable, 5 as deﬁnite) ×10
Hematocrit of <0.47 in men and <0.42 in women ×6
Percentage deviation from standard weight ×1
Source: Best et al. [32].
Remission of CD is deﬁned as CDAI below 150. Severe disease is deﬁned as a value of greater than 450.
aOne point each is added for each set of complications: (a) the presence of joint pains (arthralgia) or frank arthritis; (b) inﬂammation of the iris or uveitis; (c) the
presence of erythema nodosum, pyoderma gangrenosum, or aphthous ulcers; (d) the presence anal ﬁssures, ﬁstulae, or abscesses; (e) the presence of other
ﬁstulae; (f). Fever during the previous week.
50.3 Treatment of Crohn’s disease
The choice of therapy is based on anatomic location, severity,
and behavior of disease. Severity can be assessed by the CD
activity index (CDAI), a score based on daily symptoms and
repercussions of CD such as hematocrit, weight, and other
factors (Table 50.1).
CDcanbe classiﬁed asmild ormild–moderate (CDAI between
150 and 220), moderate or moderate–severe (CDAI between 220
and 450), or severe or severe/fulminant (CDAI >450). There is a
current trend to use CRP levels in conjunction with the CDAI to
evaluate severity of the disease [4,33]. Disease remission is
deﬁned in the majority of clinical trials as a CDAI of less than
150 [34]. Response is often deﬁned by a variation of CDAI of
100 points ormore, although a variation of 70 points ormore has
been used in some studies. The perineal disease activity index
(PDAI) is sometimes used if perineal lesions are predominant.
Endoscopic evaluation can be standardized using the CD endo­
scopic index of severity (CDEIS) or a simpliﬁed variant, the
simple endoscopic score for CD (SESCD) [35].
50.3.1 Current treatment options for Crohn’s
disease
Current treatment strategies include oral 5-aminosalicylates
(sulfasalazine, mesalamine), antibiotics (metronidazole, cipro­
ﬂoxacin), topically or systemically acting steroids (controlled
ileal release budesonide or prednisone), and immunomodulator
therapy, including azothioprine, 6-mercaptopurine, methotrex­
ate, calcineurin inhibitors (cyclosporine, tacrolimus) and anti-
TNF antibodies (inﬂiximab, adalimumab, certolizumab pegol).
Nutritional therapy (elemental or polymeric diets) can be con­
sidered as an adjunct treatment. Mildly to moderately active
localized ileocecal disease can often be managed with budeso­
nide, while severe active or extensive disease generally requires
systemic corticosteroids with or without an immunomodulator.
Anti-TNF therapy, used alone or in adjunction to an immuno­
modulator, is recommended in moderate to severe or extensive
relapsing disease or in previously steroid-refractory, -dependent,
or -intolerant patients. All currently available anti-TNF therapies
appear to have similar efﬁcacy.
If there is loss of response to anti-TNF therapy, increasing doses
or frequency of administration can be tried before switching to
another anti-TNF agent. Surgery should be considered in localized
disease. Treatment of relapse is essentially based upon previously
successful therapies, but other factors such as patient preference,
time to relapse, concurrent therapy, and adherence to therapy are
taken into account.The choiceofmaintenance therapy is essentially
based upon the course and extent of disease, and the effectiveness
and tolerance of previously used treatments. Some patients do not
need maintenance. Azathioprine is generally the ﬁrst choice,
followed by methotrexate and anti-TNF therapy [36].
Perianal and ﬁstulizing disease can be treated by surgery,
including surgical drainage, ﬁstulotomy and setons, advance­
ment ﬂaps, antibiotics, or an immunomodulator (including anti-
TNF agents) [33]. A seton or seton stitch is a procedure used to
aid the healing of ﬁstulas. The procedure involves running a
surgical-grade cord through the ﬁstula tract so that the cord
creates a loop that joins up outside theﬁstula. The cord provides a
path that allows the ﬁstula to drain continuously while it is
healing, rather than allowing the exterior of the wound to close
over. Keeping the ﬁstula tract open can help keep from trapping
pus or other infectiousmaterial in thewound. The procedurewas
mentioned by Hippocrates in 400 BC. Flap surgery is a technique
in plastic and reconstructive surgery where any type of tissue is
lifted from a donor site and moved to a recipient site with an
intact blood supply. Advancement ﬂaps are used when the
patient is in overall good health and the defect is free of tumor
and obvious infection.
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Figure 50.6 Chronic UC. The image shows a view of a longitudinal section
through the colon wall. This demonstrates not only the angry red mucosa
but also the tendency for the inﬂamed tissue to throw itself up into
inﬂammatory pseudopolyps. (See color plate section.) Source: http://
commons.wikimedia.org/wiki/File:Chronic_Ulcerative_Colitis_1
.jpg#mediaviewer/File:Chronic_Ulcerative_Colitis_1.jpg.
Whereas 80–90% of the patients can be satisfactorily treated
with these approaches, some patients are refractory, intolerant,
or lose response to them. In this setting, few options are left apart
from debilitating surgery with a permanent stoma or experi­
mental treatments. Images of surgical resections are shown in
Figures 50.6 and 50.7.
50.3.2 Potential treatment options
New therapies that have demonstrated some efﬁcacy are inhib­
iting leucocyte migration, targeting inﬂammatory cytokines,
enhancing immune regulatory mechanisms, and/or promoting
tissue repair.
Figure 50.7 Colonic pseudopolyps of a patient with chronic severe
intractable UC. Colectomy specimen. (See color plate section.) Source:
http://commons.wikimedia.org/wiki/File:Chronic_Ulcerative_Colitis_1
.jpg#mediaviewer/File:Chronic_Ulcerative_Colitis_1.jpg.
50.3.2.1 Drugs targeting leucocyte homing
Alpha-4 integrins are members of the cell-surface adhesion
family expressed by several cells, including leucocytes, and
binding several ligands, including VCAM-1 expressed on endo­
thelial cells, and extra-cellular matrix proteins such as ﬁbronec­
tin. These interactions lead to various cellular processes, such as
activation, proliferation, and migration of α4-integrin-express­
ing cells toward sites of inﬂammation, including areas of the gut
in CD [37]. Natalizumab, a humanized monoclonal antibody
against the α4 subunit of both α4β1 and α4β7 integrins, has
demonstrated therapeutic beneﬁt in patients with moderate to
severe active CD. In the ENACT-1 randomized clinical trial
(RCT) evaluating natalizumab versus placebo as induction ther­
apy in 905 patients with active CD, similar rates of response
(decrease in CDAI of 70 points) and remission (CDAI <150)
were observed at week 10 (respectively 56% versus 49%,
P  0:05, and 37% versus 30%, P  0:12). In a second part of
the trial (ENACT-2) evaluating natalizumab versus placebo as
maintenance therapy in 339 patients who had a response to
natalizumab in the ﬁrst trial, a signiﬁcantly higher rate of
sustained response (61% versus 28%, P < 0:001) and remission
(44% versus 26%, P  0:003) was observed at week 36 [38]. In
ENCORE, an RCT evaluating the efﬁcacy of natalizumab versus
placebo as induction therapy in 509 patients with moderately to
severely active CD and active inﬂammation (CRP >2.87mg/L),
signiﬁcantly higher rates of response (decrease in CDAI of
70 points) at week 8 and remission (CDAI<150)were observed
(respectively 48% versus 32%, P < 0:001, and 26% versus 16%,
P  0:002) [39]. In a meta-analysis of ﬁve trials comparing
natalizumab with placebo, the relative risk (RR) of not achieving
remission was reduced with natalizumab (0.88) [40]. In the USA,
monotherapy with natalizumab is indicated for inducing and
maintaining clinical response and remission in adult patients
with moderately to severely active CD and evidence of inﬂam­
mation who have had an inadequate response or who are unable
to tolerate conventional CD therapies and anti-TNF agents [33].
The most dangerous adverse effect is progressive multifocal
leukoencephalopathy caused by the JC virus.
Vedolizumab, a humanized anti-α4β7 integrin monoclonal
antibody, has also been approved by the US Food and Drug
Administration and the European Medicine Agency for use in
patients with moderate to severe CD. In the induction phase
comparing intravenous vedolizumab therapy (300mg) versus
placebo in 368 adults with active CD, a higher rate of clinical
remission (CDAI 150) was observed (14.5% versus 6.8%,
P  0:02), while CDAI-100 response was similar (31.4% versus
25.7%, P  0:23). In the maintenance phase comparing intra­
venous vedolizumab therapy every 8 or 4weeks versus placebo in
461 patients who had had a response to vedolizumab, there was a
signiﬁcantly higher rate of clinical remission (39.0% and 36.4%
for the two vedolizumab groups, respectively, versus 21.6% for
the placebo group; P < 0:001 and P  0:004), but also a higher
rate of serious adverse events (24.4% versus 15.3%) and infec­
tions (44.1% versus 40.2%) [41].
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Chemokine receptor 9 (CCR9) is a highly speciﬁc receptor
expressed predominately by T cells. Its overexpression leads to
the migration of T cells to the small and large intestines. In
PROTECT-1, an RCTwith 436 subjects suffering frommoderate
to severe CD (CDAI between 250 and 450 andCRP>7.5mg/L), a
CCR9 antagonist (CCX282-b/Traﬁcet-EN) given 250mg twice
daily for 36 weeks demonstrated efﬁcacy in maintaining remis­
sion in patients identiﬁed as responders (decrease in CDAI of
70 points) after the induction phase (47% of subjects on
CCX282-B in remission at 36 weeks versus 31% on placebo;
P  0:01). CCX282-B was also superior to placebo in normaliz­
ing CRP at week 36 (19% versus 9%; P  0:04), and decreasing
the number of subjects requiring corticosteroid rescue therapy
(11% versus 21%, P  0:04). Serious adverse events occurred in
similar rates in the two groups [42].
Other molecules targeting T cells, but not interfering with
homing, have been studied with less success. Visilizumab, a
humanized monoclonal antibody directed at the cell surface
marker CD3 expressed only by activated T cells, inducing
selective apoptosis of these activated T cells, has shown some
efﬁcacy in an uncontrolled trial [43] but was associated with an
increased rate of adverse events, including cytokine release
syndrome and liver toxicity [44].
Cytokine release syndrome is a common immediate compli­
cation occurring with the use of anti-T cell antibody infusions
such as antithymocyte globulin (ATG), OKT3 (muromonab­
CD3), and TGN1412, and also with the CD-20 antibody ritux­
imab against B cells. Severe cases are known as cytokine storms.
The antibodies bind to the T cell receptor (TCR), activating the T
cells before they are destroyed. The cytokines released by the
activated T cells produce a type of systemic inﬂammatory
response similar to that found in severe infections and charac­
terized by hypotension, pyrexia, and rigors. The patient feels very
unwell, as if in a high fever – indeed, the cytokine release
syndrome is effectively a type of noninfective fever. Deaths
due to cytokine release syndromewithOKT3have been reported,
and it can cause life-threatening pulmonary edema if the patient
is ﬂuid overloaded. However, if treated appropriately it is usually
not dangerous, just extremely unpleasant for the patient.
Abatacept, a CTLA-Ig (cytotoxic T-lymphocyte-associated
protein) that blocks the co-activation of T cells by competing
withCD28 forCD80/CD86, andwhich is used in the treatment of
rheumatoid arthritis, was not found to be effective in CD [45].
50.3.2.2 Drugs targeting the proinﬂammatory cascade
The proinﬂammatory cytokines IL-12 and IL-23 are involved in
Th1 and Th17 responses respectively, and both are implicated in
the pathogenesis of CD [46]. Ustekinumab, a humanmonoclonal
antibody blocking the p40 common subunit of IL-12 and IL-23,
was evaluated in a phase II RCT with 526 adults suffering from
moderate-to-severe CD that was resistant to TNF antagonists. In
the induction phase, clinical response at 6 weeks was signiﬁcantly
higher in a subgroup of patients receiving 6mg/kg of ustekinumab
intravenously (39.7% versus 23.5% in the placebo group,
P  0:005), while there was no signiﬁcant difference in clinical
remission. In the maintenance phase of the trial, comparing 90mg
of ustekinumab subcutaneously versus placebo in 145 patients
who had a response to ustekinumab at 6 weeks, signiﬁcantly
increased rates of clinical response (69.4% versus 42.5%,
P < 0:001) and remission (41.7% versus 27.4%, P  0:03) at 22
weeks [47]. Phase III trials are currently underway to evaluate the
safety and efﬁcacy of ustekinumab (www.clinicaltrials.gov;
NCT01369355, NCT01369342, NCT01369329).
The proinﬂammatory cytokine IL-6 has been implicated in the
pathogenesis of colitis in various animal models and in patients
with CD [48,49]. In a small pilot study with 36 patients suffering
from active CD, a biweekly 8mg/kg infusion of tocilizumab, an
anti-IL-6 receptor humanized monoclonal antibody used in
rheumatoid arthritis, showed promising results with 8/10
(80%) patients experiencing a clinical response compared with
4/13 (31%) patients in the placebo group (P  0:019), although
only two patients achieved remission. The incidence of adverse
events was similar in the two groups [50].
Thalidomide has anti-inﬂammatory effects, by decreasing the
production of proinﬂammatory cytokines, including TNF-α and
IL-12. It appears to be effective in inducing remission in refrac­
tory pediatric CD, as shown in a randomized controlled trial with
56 children with active CD despite immunosuppressive treat­
ment (prolonged by an open-label extension of the study, where
nonresponders to placebo received thalidomide). Overall, 32/49
(65.3%) patients treated with thalidomide achieved a response
(reduction in pediatric CDAI by 75%) and 31/49 (63.3%)
achieved clinical remission [51].
Since IL-17 and IFN-γ have been identiﬁed as major actors in
the pathogenesis of CD, molecules inhibiting these agents have
been developed. However, anti-IL-17 antibodies (secukinu­
mab [52], brodalumab [53]) and anti-IFN-γ antibodies (fonto­
lizumab [54]) all failed to demonstrate efﬁcacy. Despite
encouraging preliminary results, attempts to administer anti­
inﬂammatory cytokines, such as IL-10 [55,56] and IL-11 [57,58],
were also disappointing, as no signiﬁcant improvement was
observed.
50.3.2.3 Other treatments
Some other treatments have been studied with encouraging
preliminary results, including human growth hormone [59],
linoleic acid [60], low-dose naltrexone [61], helminths [62,63],
or extracorporeal photopheresis [64]. Larger studies are needed
to conﬁrm these results. Other agents have so far failed to
demonstrate efﬁcacy including granulocyte colony-stimulating
factor (G-CSF) and granulocyte-macrophage colony-stimulating
factor (GM-CSF) [65,66], probiotics [67–70], andprebiotics [71].
If intestinal failure occurs, home parenteral nutrition and intes­
tinal transplantation can be discussed [72]. Interestingly, several
cases of CD recurrence after intestinal transplantation have been
reported [73–75], which may indicate that the immune system
plays a more important role than the mucosal barrier in the
pathogenesis of CD.
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50.3.2.4 Bone marrow transplantation and stem
cell therapy
The ﬁrst reported success of autologous hematopoietic stem
cell transplantation (HSCT) in CD was published in 1993 in a
patient with non-Hodgkin’s lymphoma [76]. Since then, at
least 19 cases of autologous or allogeneic HSCTs for malig­
nancies in CD patients have been reported, with remission of
CD achieved in most cases, even after discontinuation of any
immunosuppressive therapy [77]. Given these results, HSCT
trials in patients with CD refractory to conventional therapy
were initiated. In 1995, the Autoimmune Diseases Working
Party of the European Group for Blood and Marrow Trans­
plantation recommended the use of autologous rather than
allogeneic HSCT because of the lower risk of severe toxic­
ity [78]. The largest study is a phase I–II trial on 24 patients
with severe CD (CDAI >250 and/or Crohn Severity Index
>16) despite anti-TNF therapy, who underwent autologous
HSCT after mobilization of their peripheral blood hemato­
poietic stem cells (HSCs) with cyclophosphamide and G-CSF,
ex vivo HSC enrichment by CD34+ selection, and non-marrow
ablative preparation with cyclophosphamide and equine or
rabbit ATG.
All patients went into remission (CDAI <150). After 5 years,
the percentage of clinical relapse-free survival was 19% and the
percentage of patients in remission, steroid-free, or medication-
free was at least 70%, 80%, and 60% respectively. Infectious
complications were frequent, including early bacteremia and/or
central venous line infection (six patients) and late infections (10
cases, including seven severe infections, in the ﬁrst year after
transplantation) [79]. A randomized phase III study was initi­
ated, but recruitment was halted prematurely for safety reasons
(http://clinicaltrials.gov/ct2/show/NCT00297193). Preliminary
results on 48 patients after 1 year follow-up showed decreases
in mean CDAI from 324 to 161, CRP from 16.6 to 6.5mg/L, with
six patients achieving a normal CDAI and three patients allowed
to stop immune-suppressivemedications. However, high rates of
adverse events were observed (100 serious adverse events, among
which 42 infective episodes requiring or prolonging hospitaliza­
tion and eight patients with temporary ﬂare of CD activity or a
need for surgery) [80].
50.4 Treatment of ulcerative colitis
The choice of therapy is based on the activity, distribution, and
pattern of disease. Disease activity can be evaluated by Truelove
and Witts’ criteria (number of bloody stools/day, pulse, temper­
ature, hemoglobin, and erythrocyte sedimentation rate or CRP)
or the Mayo score, and is classiﬁed as mild, moderate, or severe.
Remission is deﬁned as complete resolution of symptoms and
endoscopic mucosal healing. Response is deﬁned as clinical and
endoscopic improvement (generally a decrease in the activity
index of >30%, associated with a decrease in the rectal bleeding
and endoscopic scores in the Mayo score) [2].
50.4.1 Current treatment options for
ulcerative colitis
Current treatment strategies include oral 5-aminosalicylates (sul­
fasalazine, mesalamine), antibiotics (metronidazole, ciproﬂoxa­
cin), topically or systemically acting steroids (prednisone,
beclomethasonedipropionate), and immunomodulatory therapy,
including azathioprine, 6-mercaptopurine, calcineurin inhibitors
(cyclosporine, tacrolimus), and anti-TNF antibodies (inﬂiximab,
adalimumab, golimumab). Surgery (procolectomy with ileo-anal
anastomosis) is an option to treat acute severe colitis or tomanage
refractory disease (see Figures 50.5 and 50.7) [81].
50.4.2 Potential new treatment options
Themost promising therapies forUCare essentially acting through
an inhibition of leukocyte migration or inﬂammatory cytokines.
Several anti-integrin antibodies have been studied inUC, including
vedolizumab [82], which has been recently approved by the US
Food and Drug Administration, and etrolizumab, a humanized
monoclonal antibody targeting the β7 subunit of α4β7 and
αEβ7) [83,84] and PF-00547,659, a monoclonal antibody to MAd-
CAM [85], which have been found effective in preliminary trials.
Alicaforsen, an inhibitor of intracellular adhesion molecule-1
[86–88], and tofactinib, a Janus kinase-3 inhibitor [89], have also
shown promising results in UC. The roles of methotrex­
ate [90–94], probiotics, and fecal microbiota transplanta­
tion [95,96] in the treatment of UC are still debated, and
randomized controlled trials are needed to evaluate their effec­
tiveness. Despite encouraging preliminary results, anti-IL-2
receptor (daclizumab [97,98], basiliximab [99–101]) and anti­
CD3 (visilizumab [102–104]) monoclonal antibodies have failed
to demonstrate efﬁcacy in larger trials. Rituximab (an anti-CD20
antibody against B cells) is ineffective and can even mediate
exacerbation of UC [105–107].
50.5 Properties of mesenchymal
stromal cells
Mesenchymal stromal cells (MSCs) are multipotent progenitors
within the bone marrow and all other vascularized organs that
are capable of differentiating into various cells and tissues, such
as chondrocytes, osteoblasts, and adipocytes in vitro [108].MSCs
can be isolated after ex vivo culture of the plastic-adherent
mononuclear cell fraction. After ex vivo expansion human
MSCs have a ﬁbroblast-like morphology, and are uniformly
positive for CD29, CD44, CD71, CD73, CD90, CD105,
CD106, CD120a, CD124, and CD166 but do not express com­
mon hematopoietic markers such as CD14, CD45, or CD34. No
marker speciﬁc for MSCs has been found yet. The International
Society for Cellular Therapy has proposed three minimal criteria
to deﬁne MSCs: (1) adhesion to plastic in standard culture
conditions, (2) expression of CD105, CD73, and CD90, and
lack of expression of CD45, CD34, CD14 or CD11b, CD79a or
CD19, and human leukocyte antigen (HLA)-DR surface
738 Section VI The therapeutic application of mesenchymal stromal cells
molecules, and (3) in vitro differentiation into osteoblasts, adi­
pocytes, and chondroblasts [109]. MSCs can be isolated from
bone marrow and many other tissues, including umbilical
cord [110], umbilical cord blood [111], placenta [112], adipose
tissue [113], gingival tissue [114], skin [115], lung [116],
liver [117], heart, and spleen [118]. They are pericytes residing
in the endothelium in the connective tissues ofmost organs [119].
50.5.1 Immunomodulation
MSCs also exert powerful immunomodulatory effects, including
inhibition of proliferation and function of T cells, B cells, and
natural killer (NK) cells. These properties have been demon­
strated in vitrowith both murine and human cells, and in vivo in
murine models of experimentally induced colitis. Dextran
sodium sulfate (DSS) and trinitrobenzene sulfonate (TNBS)
are commonly used to induce colitis in mice, by initiating
epithelial cell lesions and altering the epithelial barrier integrity.
Both acuteDSS- andTNBS-induced colitis are characterized by a
Th1–Th17-mediated acute inﬂammation with increased TNF-α,
IL-6, IL-17 and increased IL-12, IL-17, IFN-γ respectively.
However, while chronic TNBS-induced colitis is associated
with an enhanced Th1/Th17 intensity of response, chronic
DSS-induced colitis switches to a Th2-biased (IL-4, IL-10)
proﬁle. Similarly, histological DSS-colitis features are “UC­
like” (epithelial disruption, focal lesions, superﬁcial inﬂamma­
tion), while histological TNBS-colitis features are “CD-like”
(transmural inﬂammation and edema) [120].
The ﬁrst observed immunomodulatory effect of MSCs was
their ability to inhibit T cell proliferation in vitro [121–123]. This
phenomenon was observed independently of whether the T cells
were CD4+ or CD8+, naive or memory T cells [124], stimulated
with allogeneic cells or nonspeciﬁc mitogens [123], and regard­
less of their functional state or the type of TCR expressed [125].
The immunosuppressive activity of MSCs is independent of the
major histocompatibility complex (MHC), as inhibition is simi­
lar using third-party MHC-unmatched MSCs or MSCs that are
autologous to the responder or stimulating lymphocytes [121].
MSC-inhibited T cells do not undergo apoptosis [123], but are
blocked in the G0/G1 phase of the cell cycle in a state of anergy by
inhibition of cyclin D2 expression [126]. Whether in vitro
addition of IL-2 can [122] or cannot [127] reverse this inhibition
is controversial. However, a recent study found that the systemic
infusion of murine BM-MSCs induced T cell apoptosis via the
FAS ligand/FAS pathway, and that FASL /  bone-marrow­
derived MSCs (BM-MSCs) could not ameliorate DSS-induced
colitis in mice [128]. Interestingly, it has been demonstrated that
FAS-mediated apoptosis is lower in the T cells of people with CD
than in control T cells [129]. However, another study demon­
strated that in vitro MSCs prevented activation-induced cell
death through downregulation of Fas receptor and Fas ligand
on TCR-activated T cells [127]. It is important to note that the
effect of MSCs on T cells seems dependent on the MSC/T cell
ratio: a high MSC/T cell ratio exerts strong inhibitory effects,
while low MSC/T cell ratios enhance T cell proliferation [130].
Other studies suggest that an important part ofMSC-mediated
immunomodulation results from the recruitment of immune-
regulatory T cells (Tregs), which can be either CD4+ CD25+
FoxP3+ orCD8+ fromboth naive andmemoryT cells [131–133].
In vivo, MSC-mediated Treg expansion has been observed in
several immune-mediated diseases, including experimental
autoimmune encephalomyelitis [134], experimental arthri­
tis [135], and type 1 diabetes mellitus [136]. Mechanisms of
this T-reg expansion appear multiple and include secretion of
soluble factors by MSCs, such as prostaglandin E2 (PGE2) and
TGF-β1 [137–139] or HLA-G [140,141], interaction between
MSCs and chemokine ligand 1 and chemokine receptor 8 on T
cells [142], and induction of immature DC [143] and mono­
cytes [144] to a regulatory proﬁle. MSC-mediated T cell modu­
lation was observed in several DSS- and TNBS-induced colitis
mouse models, treated with intravenous or intraperitoneal injec­
tion of human adipose-derived MSCs (ASCs) [145], umbilical­
cord-derivedMSCs (UCMSCs) [146,147], or BM-MSCs [148]. In
these studies, MSCs effectively treated colitis with both a clinical
response and histological improvement, showing decreased inﬁl­
tration of inﬂammatory cells in the lamina propria. The investi­
gators mostly observed a decreased number of IFN-γ-producing
Th1 cells and higher numbers of CD4+ CD25+ Foxp3+ Tregs in
mesenteric lymph nodes and the lower colon and systemic levels
of Th1 and Th17 proinﬂammatory cytokines, including TNF-α,
IFN-γ, IL6, IL-12, IL-17, and IL-23, as well as higher colonic and
systemic levels of the anti-inﬂammatory/regulatory cytokine
IL-10. In a murine model of TNBS-induced colitis, MSCs co­
localized with CD11b+ cells in the spleen, and these cells were
essential to the expansion of Tregs in draining mesenteric lymph
nodes [149]. In another murine model of TNBS-induced colitis,
intravenous injection ofmurine BM-MSCs was followed not only
by downregulation of both Th1 and Th17 responses and activa­
tion of regulatory T cells, but also by a signiﬁcant upregulation of
Th2 activities (IL-4, IL-10, GATA-3) [150].
The effect of MSCs on B cells remains controversial, and may
depend on environmental signals. According to most authors,
MSCs inhibit B cell activation, proliferation, chemotaxis, and
immunoglobulin G secretion, both in murine [126,151,152] and
human [153] studies. In these studies, B cells were enriched from
the spleen or puriﬁed from peripheral blood and were exposed to
various stimuli, including allogeneic cells, mitogenic agents and
lipopolysaccharide. Inhibition of B cell function wasmediated by
soluble factors in transwell experiments. In another study, B-cell
co-stimulatory molecule expression and cytokine production
seemed unaffected by human MSCs [153]. However, in a study
of highly puriﬁed B cells, MSCs promoted proliferation and
differentiation into immunoglobulin-secreting cells of naive B
cells isolated from healthy donors and total B cells from children
with the autoimmune disease systemic lupus erythematosus
(SLE), stimulated with an agonist of toll-like receptor (TLR) 9
in the absence of B cell receptor triggering [154].
The relationship between MSCs and NK cells is complex
and also not yet fully understood. MSCs inhibit the IL-2- or
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IL-15-driven proliferation of human resting NK cells and their
production of IFN-γ, TNF-α, and IL-10 [155,156], but their
effects on the cytotoxic activity of NK cells is controversial. Some
authors report have reported MSC-mediated decreased NK cell
cytotoxicity [140,156,157], while others have not observed this
effect [158,159]. This discrepancy might depend on MSC/NK
ratios or on whether NK cells were freshly isolated or not [155].
MSCs also interact with antigen-presenting cells, including
DCs. MSCs inhibit differentiation of DC precursors, such as
monocytes or CD34+ hematopoietic progenitors into mature
DCs, by blocking them in the G0/G1 phase of the cell cycle,
through a downregulation of cyclin D2 and p27Kip1 expres­
sion [160]. DCs cultured with MSCs have impaired antigen-
presenting [161] and migration [162] functions and show
increased secretion of IL-10 and decreased production of
IL-12 [163]. These effects have been conﬁrmed in vivo in murine
models [164]. MSCs also induce DC precursors (CD34+ hema­
topoietic progenitors) [165] and mature DCs [166] to differenti­
ate into a regulatory DC population through the Notch signaling
pathway.
MSCs may also modulate the functions of macrophages, for
example, through increased IL-10 secretion [167] or induction
into a regulatory-like proﬁle [144]. In vitro addition of increasing
numbers of monocytes or DCs into co-cultures of human ASCs
and activated CD4+ cells progressively inhibited T cell prolifer­
ation and IFN-γproduction [145]. Inmurinemodels ofDSS- and
TNBS-induced colitis, the intraperitoneal injection of murine
bone marrow macrophages co-cultured with ASCs was effective
in treating both colitis and sepsis. In vitro these macrophages
showed a regulatory phenotype that was different from activated
macrophages and characterized by high arginase activity and
increased expression of IL-10 and inducible nitric oxide synthe­
tase (iNOS) upon restimulation with lipopolysaccharide, while
secreting low levels of the inﬂammatory cytokines TNF-α
and IL-12. They showed potent immunosuppressive activity
on splenocytes that was signiﬁcantly reversed by the iNOS
inhibitor L-NG-nitroarginine methyl ester and IL-10-blocking
antibodies [168].
Thus the mechanisms of MSC-mediated immunomodulation
arenot yet fully elucidated andprobably vary amongspecies [169].
They include direct cell-to-cell contact through the expression of
adhesion molecules and secretion of soluble factors. Multiple
factors are involved, including PGE2 [156,167,170], indoleamine
2,3-dioxygenase [114,156,171], nitric oxide [172,173], HLA­
G [140,174], TGF-β and hepatocyte growth factor [123], IL-1
receptor antagonist [175], TNF-stimulated gene 6 protein [176],
and IL-10, which, although probably not secreted directly by
MSCs, also participates in the immunosuppressive effect ofMSCs,
as IL-10 blockade partially reversed the colitis and sepsis in the
murinemodel [145]. In theDSSmurinemodels ofDSS- orTNBS-
induced colitis, PGE2 produced by nucleotide-binding oligomer­
ization domain-containing protein-2-activated human UCMSCs
increased production of IL-10 and Tregs and was required to
reduce the severity of colitis [177].
Transcriptional repression of the proinﬂammatory cytokine
early T cell activation factor 1 (osteopontin) by the autoimmune
regulator (AIRE) has also been implicated in MSC immunomo­
dulation as it was required for the efﬁcacy of BM-MSC adminis­
tration in a model of chronic colitis by transfer of CD4+
CD45RBhi T cells in Rag / mice.However, AIRE did not control
MSC suppression of T cell proliferation in vitro [178].
The immunomodulatory effects of MSCs depend on the
inﬂammatory environment and in some circumstances MSCs
can act as immune-stimulating cells. TLRs have an important
role in inducing MSCs into an immunosuppressive or immu­
nostimulating pathway, as different TLR agonists inﬂuenceMSC
proliferation, differentiation, migration, and immunomodula­
tory functions in different ways [179–181]. Many inﬂammatory
cytokines promote MSC-mediated immunosuppression, includ­
ing IFN-γ, TNF-α, and IL-1β [173]. Pretreatment of human BM-
MSCs with IFN-γ increased expression of MHC class II
molecules, indoleamine 2,3-dioxygenase, and iNOS and sig­
niﬁcantly inhibited peripheral blood mononuclear cell
(PBMC) proliferation at lower PBMC :MSC ratios. In murine
models of DSS- and TNBS-induced colitis, intraperitoneal
administration of INF-γ-pretreated MSCs was more effective
in treating colitis, in reducing serum amyloid A levels, in
reducing colonic inﬂammatory cytokines (TNF-α, IL-6, IFN-γ,
and IL-17A), and in increasing migration into inﬂamed intes­
tine [182]. Similarly, IL-1β-primed human UCMSCs signiﬁ­
cantly attenuated the development of DSS-induced murine
colitis, increased the number of peritoneal M2 macrophages
and splenic or mesenteric lymph node Tregs, and enabled
migration more efﬁciently into the spleen, mesenteric lymph
nodes, and colon, which was related to upregulation of CXCR4
expression. IL-1β stimulation elevated COX-2, IL-6, and IL-8
mRNA expression in MSCs [183].
50.5.2 Immune tolerance
Human MSCs are immunoprivileged cells because they express
low levels of HLA class I molecules and do not express HLA class
II molecules nor the co-stimulatory molecules CD80, CD86, and
CD40 under normal circumstances [184,185]. However, expres­
sion of HLA class I antigens, even at a low level, may be
responsible for vulnerability of MSCs to activated NK-cell
lysis [186]. Moreover, a recent study observed the capacity of
murine MSCs to present extracellular antigen through their
MHC class I molecules by cross-presentation and to induce
an effective CD8+ T cell immune response [187]. In addition, it
has been demonstrated in vivo that, in the presence of a narrow
window of IFN-γ, MSCs upregulate expression of MHC class I
and II molecules and are able to act as antigen-presenting cells
and stimulate CD4+ cell proliferation [188–190]. This immuno­
genicity has also been observed in vivo in animalmodels inwhich
donor-derived MSCs, unlike autologous MSCs, could promote
bonemarrow [191] or skin graft [192] rejection. Systemic or local
administration of allogeneic MSCs in rats resulted in the devel­
opment of anti-donorT cell and antibody responses, which could
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promote a rapid clearance ofMSCs and a limitation of their long-
term beneﬁts [193,194].
50.5.3 Tissue regeneration
MSCs can differentiate in vitro to cells of the mesenchymal
lineage. The relative importance of this property for the efﬁcacy
ofMSCs in experimental colitis and IBD is still being investigated.
50.5.4 Homing
MSCs are able to selectively home to sites of tissue injury and
inﬂammation, including intestine, kidney, lung, liver, thymus
and skin [195] (and see Chapters 22–24). In murine models of
colitis, MSCs have demonstrated their ability to migrate selec­
tively into inﬂamed zones of the intestine, mesenteric lymph
nodes, and spleen, whether they were murine or human, bone
marrow, adipose, or umbilical cord derived, and whether admin­
istered intravenously or intraperitoneally [145,147–149,196].
MSCs have been found in the lamina propria [196], themuscular
layer, and the submucosa of the inﬂamed intestine [197]. How­
ever, homing capacities may be altered in MSCs that have been
cryopreserved. In a murine model of TNBS-induced colitis,
intraperitoneally but not intravenously injected cryopreserved
MSCs were found in the inﬂamed colon [197]. MSCmigration is
directed by a multitude of signals depending on theMCS source,
type or environment, and growth factors and cytokines
involved [198,199]. In order to better understand the selective
migration of MSCs into the inﬂamed intestine, Gonzalez-Rey
et al. [145] studied the expression of various chemokine receptors
involved in cell recruitment to inﬂammatory sites and demon­
strated that human ASCs expressed on their surface the chemo­
kine receptors CCR1, CCR2, CCR4, CCR5, CCR7, CCR9,
CXCR1, and CXCR5 and that most of these receptors were
functional since human ASCs migrated in response to chemo­
kines such as CCL5, CCL22, CCL19, CCL25, CXCL8, and
CXCL13. Moreover, human ASCs expressed a panel of adhesion
molecules involved in tissue transmigration, including CD54,
CD49e, CD44, CD29, CD105, CD106, and CD166. Activation
and targeting may improve delivery of MSCs into mesenteric
lymph nodes and colon, and hence their efﬁcacy in murine
colitis, as demonstrated with IFN-γ- [182] or IL-1β-primed
MSCs [183] and VCAM antibody-coated MSCs (AbVCAM-1­
MSCs) [200]. IFN-γ upregulates expression of the chemokine
receptor CXCR7, lectins LGALS3BP and LGALS9 and
ADAM15, a matrix metalloproteinase involved in epithelial
adhesion [182], while IL-1β upregulates CXCR4 expres­
sion [183]. How long MSCs do stay into the inﬂamed intestine
is unknown, but it seems that they remain there for at least
2 weeks [147].
50.5.5 Differentiation and stimulation of
tissue repair
In addition to their capacity to differentiate into chondrocytes,
osteoblasts and adipocytes, MSCs can also differentiate into
other cells of the mesenchymal lineage, such as myoblasts [201]
or cardiomyocytes [202]. Moreover, UCMSCs [203] and BM-
MSCs have shown an ability to differentiate in vitro into cells of
ectodermal lineage, such as neuroglial cells [204,205], and of
endodermal lineage, such as renal tubular epithelial cells [206]
and hepatocytes [207–209], although this a controversial area;
andwhileMSCsmay take on themorphological and even the cell
surface markers of, for example, neurons, there is little, if any,
evidence that they function as neurons. This not to say that they
are not beneﬁcial in the treatment of diseases involving damaged
neurons, but they most likely mediate this effect by secretion of
paracrine factors and by modulation of the inﬂammatory
reaction.
As indicated earlier, in response to inﬂammation or tissue
injury, MSCs are capable of engrafting in many tissues [210],
albeit transiently, and have demonstrated their efﬁcacy in pro­
moting tissue repair in myocardial infarction [211], kidney
diseases [212,213], liver diseases [214], lung diseases [215]
and injury [216], and neurological disorders [217]. In DSS-
induced colitis in rats, intravenous injection of rat MSCs enabled
signiﬁcant healing of epithelial injuries, and the MSCs extracted
from the lamina mucosa had upregulated their expression of
α-smooth muscle actin, suggesting a reprogramming to myo­
genic lineage differentiation, possibly involved in intestinal
repair. In TNBS-induced colitis in rats, topical implantation
of rat BM-MSCs healed mucosal injuries. MSCs engrafted
into the submucosal layers, but only a small proportion was
positive for α-smooth muscle actin and desmin, indicating
differentiation into myoﬁbroblasts. A larger proportion of
MSCs surrounding the lesion area expressed vascular endothelial
growth factor and TGF-β1, two growth factors known to play
important roles in gastrointestinal wound healing [218]. In a
DSS-induced colitis model in rats, intravenous injection of
allogeneicMSCs resulted in clinical improvement withmarkedly
reduced epithelial injury and, signiﬁcantly, restoration of expres­
sion of claudin-2, -12 and -15, proteins constituting tight junc­
tions that play amajor role in the paracellular permeability of the
epithelial barrier [219].
Again, as indicated earlier, it is thought that the tissue repair
properties of MSCs are mainly due to their ability to stimulate
survival and recovery of local tissues, rather than to transdiffer­
entiation ability [220]. MSCs have demonstrated their ability to
stimulate angiogenesis [221] and to inhibit apoptosis and ﬁbrosis
in injured tissues [222].
50.6 Mesenchymal stromal cell
administration in inﬂammatory
bowel diseases
Two different applications of MSCs in IBDs have been evaluated
in human trials: local injection of MSCs to treat ﬁstulizing CD
and intravenous injection of MSCs to treat luminal CD or UC.
MSC administration has been studied in CD more than it has
in UC.
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50.6.1 Mesenchymal stromal cell
administration for ﬁstulizing
Crohn’s disease
Management of ﬁstulas in patients with CD is an extremely
challenging problem, because many such ﬁstulas do not respond
to available treatment, despite recent improvements using anti-
TNF agents and improvements in surgical treatments. Endoanal
advancement ﬂap is the standard surgical technique, but anal
incontinence and recurrence are not uncommon. Several trials
have evaluated the efﬁcacy of local injections ofASCs orBM-MSCs.
50.6.2 Autologous mesenchymal stromal




In a phase I study García-Olmo et al. treated four patients with
one or more refractory, complex Crohn’s ﬁstulas with a single
intraﬁstular injection of MSCs. The ﬁstulas were enterocutane­
ous, suprasphincteric, and/or rectovaginal ﬁstulas, were
unresponsive to medical treatment, and had been unsuccessfully
treated by surgery at least twice. The injection consisted of
3–30× 106 autologous ASCs from passages 1 to 3. Six of eight
(75%) ﬁstulas had healed 8 weeks after treatment, and the other
two (25%) were incompletely closed with decreased output ﬂow.
No relationshipwas found between the number of injectedMSCs
and the success of the treatment. No adverse effects were
observed within 12–22 months follow-up, and no aberrant
differentiation was seen in biopsies [223].
In a phase IIb study the same group showed that ASCs were
effective in healing 69% of complex perianal ﬁstulas in patients
with moderate to severe CD who were intolerant or resistant to
the anti-TNF agent inﬂiximab [224]. Forty-nine patients with
complex perianalﬁstulaswere included. Thirty-ﬁve of theﬁstulas
were of cryptoglandular origin and 14 were associated with CD.
Cryptoglandular anal ﬁstulas arise from inﬂammation of the
proctodeal glands of the intersphincteric space. The mucus
secretions of the anal glands empty into the anal crypts, thereby
lubricating the anus. Anal glands are present in the subepithe­
lium and the internal sphincter, with a large number also deeply
sited within the intersphincteric space. Infection of these inter-
sphincteric glands is thought to give rise to an intersphincteric
abscess if the draining duct is blocked by the resulting infectious
debris. The abscessmay resolve by spontaneous drainage into the
anal canal or itmay progress to an acute anorectal abscess that, in
most cases, subsequently develops into a perianal ﬁstula. This
type of ﬁstula is not associated with CD.
Patients were randomly assigned to the administration of an
intraﬁstular injection of ﬁbrin glue or ﬁbrin glue containing
20million ASCs. If ﬁstula healing had not occurred by 8 weeks, a
second double dose of ASCs was administered. Fistula healing
was observed in 17/24 patients receiving ASCs (71%); 11 patients
healed after the ﬁrst injection and six patients healed after a
second injection compared with 4/25 (16%) in the control group
(RR 4.43, P < 0:001). A similar proportion was observed in the
CD patients, with healing of the ﬁstula in ﬁve out of seven
patients receiving ASCs compared with one out of seven patients
in the control group (RR 5.00,P  0:10). Improvement of quality
of life, assessed by a quality-of-life questionnaire, was signiﬁ­
cantly greater in the ASC group compared with the control
group, even in patients whose ﬁstula did not heal [225]. After an
average long-term follow-up of approximately 40 months, 7 out
of 12 patients treated with ASCs remained free of recurrence
compared with two out of three in the control group. Perianal
sepsis occurred more frequently in the control group than in
the ASC group (P  0:04). No adverse effects related to ASC
administration were noted, conﬁrming their excellent safety
and tolerability proﬁle, and no patient suffered from anal
incontinence [226].
Another group performed a dose-escalation phase I study, in
which 10 patients with a perianal ﬁstula associated with CDwere
treated with an intraﬁstular injection of autologous ASCs from
passages 3 and 4 at a dose of either 1× 107 (group 1), 2× 107
(group 2), or 4× 107 ASCs/mL (group 3). The doses used were
selected with regard to the size of the ﬁstula. Eight weeks after
injection, complete healing occurred in two out of four patients
in group 2 and one out of three patients in group 3, while partial
closure with no output drainage was observed in all other
patients. After follow-up of 8 months the three patients whose
ﬁstula had been completely healedwere free of recurrence and no
adverse effects were observed [227]. The same group subse­
quently led a phase II trial studying the effects of the intraﬁstular
injection of ASCs from passages 3 and 4 in 43 patients with
perianal ﬁstulas associated with CD. The ﬁrst injection again
contained a number of ASCs that was proportional to the size of
the ﬁstula: 3× 107 ASCs per 1 cm length of ﬁstula when the
ﬁstular diameter was less than 1 cm, and 6× 107 ASCs per 1 cm
length of ﬁstula when the diameter was between 1 and 2 cm. The
average number of ASCs was 15.8× 107 cells per ﬁstula. Patients
without complete ﬁstula closure at 8 weeks received a second
injection of 1.5 times more cells than the ﬁrst injection. The
ﬁstula tract was ﬁlled with a mixture of ASCs and ﬁbrin glue.
Complete ﬁstula healing was observed in 27/42 patients (64.3%)
by 8 weeks after the ﬁnal ASC injection and was sustained after
1 year in 23/26 patients (88%). Six other patients showed
incomplete closure of the ﬁstula, of which ﬁve patients achieved
closure of more than 50% of the ﬁstula tract with a decrease in
drainage of more than 50%. Five other patients discontinued the
study before week 8. No relation was found between the outcome
of the treatment and ﬁstula type, length, or diameter or duration
of CD. No adverse events related to ASCs were observed [228].
50.6.2.2 Bone marrow-derived mesenchymal
stromal cells
The safety and efﬁcacy of serial intraﬁstular injections of autolo­
gous BM-MSCs in the treatment of ﬁstulizing CDwas studied by
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Ciccocioppo et al. in 10 patients refractory to all previous
medical treatments including anti-TNF agents or
unsuccessfully treated by surgery. They administered intra­
ﬁstular injections of 15–30× 106 MSC from passage 3 every
4 weeks until improvement was obtained or when autologous
MSCs were no longer available Patients received between two
and ﬁve injections. Sustained complete closure of the ﬁstula
tract occurred in 7/10 patients and incomplete closure in 3/10
patients as assessed by surgical exploration and MRI. MRI
provided images of regenerative tissue without ﬁbrotic tissue.
All patients had a signiﬁcant reduction of their CDAI scores:
pre- and posttreatment median values were 294± 49 and
99± 32 at 12 months after the last procedure (P < 0:001).
Their median PDAI scores pre- and posttreatment were
13.0± 2.2 and 4.5± 2.4 at 12 months after the last procedure
(P < 0:001). Patients who achieved remission had CDAI
scores 150 and PDAI scores 8, usually after the second
administration of ASCs. Lower endoscopic examination per­
formed at the end of the follow-up period demonstrated rectal
mucosal healing in seven out of seven patients. In addition,
they observed a signiﬁcant increase in the percentage of
CD25bright FoxP3+circulating CD4+ Tregs as soon as after
the second injection of ASCs which was stable at 12 months
(P < 0:01). Additionally, mucosal FoxP3+ Tregs were present
in the inﬂamed areas at 12 months (P < 0:0001). There
were no adverse effects during the procedure nor during
the 12-month follow-up period [229].
50.6.3 Allogeneic mesenchymal stromal cell
administration for ﬁstulizing Crohn’s
disease
García-Olmo and co-workers also explored the use of expanded
allogeneic ASCs for the treatment of complex perianal ﬁstulas in
patients with nonactive luminal CD (CDAI 200) in a single-
arm multicenter phase I/IIa clinical trial. Twenty-four patients
received an intraﬁstular treatment with 20× 106 allogeneic ASCs
followed by a second administration of 40× 106 ASCs if ﬁstula
closure was incomplete after 12 weeks. After 12 weeks, 12/20
patients (60.0%) had an improvement of at least one of their
ﬁstulas and complete closure occurred in 8/21 (38.1%) on clinical
examination. After 24 weeks, these values were respectively 9/13
patients (69.2 %) and 9/16 patients (56.3%). Based on a combi­
nation of clinical andMRI assessment, ﬁstula closure was seen in
6/24 patients (30%) at 24 weeks. A statistically signiﬁcant
decrease in the MRI score of severity was observed at
week 12. PDAI signiﬁcantly decreased by more than 37% com­
pared with baseline (P < 0:01). No effect was observed on the
CDAI scores. Luminal relapse was observed in 0/24 patients
(0.0%) at week 12 and in 5/24 patients (20.8%) at week 24. After a
6-month follow-up period the safety proﬁle was acceptable, with
a low number of serious adverse events: anal abscess in three
patients, pyrexia in one patient, and uterine leiomyoma in one
patient [230].
50.6.4 Autologous mesenchymal stromal cell
administration for luminal inﬂammatory
bowel diseases
Intravenous injections of autologous BM-MSCs have been tested
in a phase I trial. Nine adult patients with moderate to severe CD
with a CDAI score between 220 and 450 and whowere refractory
to conventional standard treatment, including corticosteroids,
immunosuppressive agents, or anti-TNF therapy, were treated
with two intravenous injection of 1–2× 106 cells/kg body weight
7 days apart. Three patients had a clinical response (deﬁned as a
decrease in CDAI score of 70 points) but none achieved
remission (CDAI <150), and four patients experienced worsen­
ing of their disease, requiring surgery in three cases or rescue
medication in one case within 14 weeks after BM-MSC admin­
istration. Endoscopic improvement using the SESCDwas seen in
two patients at week 6. Biopsies of inﬂamed mucosa showed a
trend to lower CD4+ T cell and higher CD4+ CD127+ Treg
numbers [231]. CD127 is the receptor for IL-7.
50.6.5 Allogeneic mesenchymal stromal cell
administration for luminal inﬂammatory
bowel diseases
Intravenous injection of allogeneic BM-MSCs has also been
evaluated with more success in a phase II pilot study. Nine
patients with refractory moderate-to-severe CD with a CDAI
score 220 and previously unsuccessful treatment with cortico­
steroids and immunomodulatory agents were randomized to
receive either a low (2× 106 BM-MSCs/kg) or a high (8× 106
BM-MSCs/kg) dose of MSCs by intravenous infusion. After 28
days all patients had a decrease in their CDAI score, with a mean
decrease of 105 (P  0:004), and three patients had a clinical
response (reduction in CDAI 100), one of whom entered
clinical remission (CDAI <150). Patients reported an increased
quality of life, as attested by a signiﬁcant increase in mean
Inﬂammatory Bowel Disease Questionnaire (IBDQ) score by
day 28 (P  0:008). No infusion reaction was observed, although
ﬁve patients experienced mild to moderate adverse events [232].
The Nanjing group, who studied the use of MSCs in the
autoimmune disease SLE, reported their experience of allogeneic
MSC transplantation in seven patients with IBD, among whom
four had CD and three had UC. They administered one intra­
venous infusion of BM-MSCs from healthy family members or
UCMSCs at a dose of 1× 106/kg body weight. Patients continued
their treatment with corticosteroids and/or immunosuppressive
agents after the transplant. After 3 months they observed a
signiﬁcant reduction in disease activity (CDAI or Clinical Activ­
ity Index) in all patients, with remission achieved in ﬁve out of
seven patients (two out of four with CD and three out of three
with UC) and endoscopic improvement with a decrease in
Endoscopic Index of Severity score or in Endoscopic Activity
Index in three out of seven patients, two out of four with CD and
one out of three with UC. Remission lasted for more than 2 years
in two patients, while two other patients relapsed at 6 and
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7 months. One CD patient had a signiﬁcant reduction in ﬁstula
size and drainage. Histological analysis of biopsy specimens
showed a reduction in the extent of the inﬂamed area and in
the lymphocytic inﬁltration in the mucosa propria. One patient
had a signiﬁcant reduction inﬁstula size and drainage.No serious
adverse events were reported after a mean follow-up of 19
months (range 6–32 months) [233].
50.7 The future of mesenchymal stromal
cell treatment in inﬂammatory
bowel diseases
50.7.1 Ongoing protocols
50.7.1.1 Mesenchymal stromal cell treatment for
ﬁstulizing Crohn’s disease
50.7.1.1.1 The Navarra study (NCT01157650)
This phase I–II study is evaluating viability, safety, and tolerance
of locally implanted autologous ASCs in 15 patients with non­
active CD (CDAI 200) and one or more enterocutaneous,
rectovaginal or complex perianal ﬁstulas. Patients should not
have perianal abscesses or rectal and/or anal stenosis, and should
not have received anti-TNF therapy or have received tacrolimus
or cyclosporine within 8 weeks and 4 weeks before MSC therapy
respectively. Secondary outcomes include an evaluation of efﬁ­
cacy (ﬁstula healing, quality of life, presence of systemic CD,
relapse) and a biological characterization of the MSCs used in
terms of their phenotype, immune suppressive capacities, and
cytokine production. This study is ongoing, but is no longer
recruiting participants (Figure 50.8).
50.7.1.1.2 The Leiden study (NCT01144962)
This dose-escalation phase I–II study aims to determine
the safety and efﬁcacy of intraﬁstular injection of allogeneic
BM-MSCs for the induction of response of active ﬁstulizing CD.
The ﬁstulas are peri-anal ﬁstulas refractory to conventional
medical treatment. Patients are randomized into one of four
groups, receiving either placebo or MSCs at doses of 10 million,
30 million, or 90 million. Exclusion criteria include acute peri­
anal infection, rectovaginal or complex peri-anal ﬁstulas with
more than two internal openings, and anti-TNF therapy less than
8 weeks prior to enrolment. Secondary outcomes at 12 weeks are
improvement of clinical and endoscopic scores, quality of life
details, and serumCRP. Safety is evaluated after 12 and 24weeks.
This study is ongoing, but is no longer recruiting participants.
50.7.1.1.3 The Anterogen studies (NCT01314092,
NCT01623453)
In a phase II trial, patients with complex perianal ﬁstulas are
randomized to receive autologous ASCs at either low (1× 109/
mL) or high (2× 109/mL) dose, followedby a seconddouble-dose
injection if complete closure is not achieved. Primary outcome is
complete closure of the ﬁstula at week 8. Safety is assessed by the
reporting of all adverse events. Subsequently, an open follow-up
clinical trial will evaluate the number of patients with sustained
complete closure and the number of adverse events 6 months
after the ﬁnal dose injection.
50.7.1.1.4 The TiGenix study (NCT01541579)
This phase III randomized double-blind placebo-controlled
multicenter study is evaluating the efﬁcacy of allogeneic ASCs
for the treatment of complex anal ﬁstulas in patients with CD.
Patients with nonactive or mildly active luminal CD (CDAI
220) and two or less complex perianal ﬁstulas are randomized
to receive either an intraﬁstular injection of 120× 106 allogeneic
ASCs or placebo. Patients with abscesses, rectovaginal ﬁstulas,
surgically treated ﬁstulas, and ongoing corticosteroid treatment
or corticosteroid within the preceding 4 weeks are excluded from
Figure 50.8 The small and large intestine with
an insert of the perianal anatomy, an area where
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the study. Primary outcomes include remission of perianal
ﬁstulizing CD at week 24 by clinical and MRI assessment. Other
outcomes are efﬁcacy, including response, time to response, and
time to remission, and assessment using the PDAI and IBDQ
criteria, as well as safety at weeks 24 and 52. This study is
currently recruiting participants.
50.7.1.1.5 The Royan study (NCT01874015)
This study is a prospective, randomized, phase I trial in which
patients with refractory CD, a CDAI score >220, and perineal
ﬁstulas are randomized to receive four monthly intraﬁstular
injections of autologous BM-MSCs with or without ﬁbroblasts.
Outcomes are ﬁstula closure and CDAI score at month 4. This
study is currently recruiting participants.
50.7.1.2 Mesenchymal stromal cell administration for
luminal inﬂammatory bowel diseases
50.7.1.2.1 The Liège study (NCT01540292)
This prospective open-label phase I–II pilot trial was initiated in
2013 to explore the safety and efﬁcacy of allogeneic BM-MSC
infusions in CD refractory or intolerant to conventional thera­
pies. Twenty patients with active refractory CD deﬁned by a
CDAI >220 despite conventional treatment, including mesala­
zine, corticosteroids, purine analogues,methotrexate, inﬂiximab,
and adalimumab, are treated with two successive injections of
1.5–2.0× 106 allogeneic BM-MSCs/kg at the beginning of the
trial and 4 weeks later. Conventional treatments of CD, such as
mesalazine, methylprednisolone, budesonide, azathioprine, 6­
mercaptopurine, or methotrexate, are allowed, while anti-TNF
antibodies are forbidden, and antibiotics are allowed only for the
treatment of a concurrent infection. The primary endpoint is a
clinical response deﬁned by a 100-point decrease in the CDAI
score at week 8. Secondary endpoints include clinical response,
remission deﬁned by a CDAI score <150, CDAI levels, CRP
levels, and fecal calprotectin levels at weeks 2, 4, 8, and 12.
Immune modulation is being investigated by monitoring of
nucleated cell counts, leucocyte subpopulations, Treg numbers,
immunoglobulin levels, Vβ repertoire of T lymphocytes, and the
quantiﬁcation of TRECS in T lymphocytes. TRECS are TCR
excision circles, which are small circles of DNA created in T cells
during their passage through the thymus as they rearrange their
TCR genes. This is a measure of thymic function. Safety is being
assessed by recording side effects, including infections.
50.7.1.2.2 TheMesoblast international studies (NCT01233960
and NCT00543374)
In a ﬁrst phase III study, patients with moderate-to-severe CD
(CDAI scores between 250 and 450)who are intolerant to, orwho
have previously failed, therapy with at least one corticosteroid
course and at least one immunosuppressive agent course and an
anti-TNF treatment are randomized into three groups to receive
a placebo or an intravenous injection of allogeneic MSCs at low
(6× 106MSCs) or high (1.2× 109) doses on four occasions over 2
weeks. The primary outcome is disease remission (CDAI score
150) at day 28, and secondary outcomes are disease improve­
ment (reduction in CDAI score of100 points), improvement in
quality of life (using the IBDQ), and reduction in number of
draining ﬁstulas. In a second phase III study, patients who
successfully achieved clinical beneﬁt in the ﬁrst study will be
enrolled and followed for duration and reinduction of clinical
beneﬁt using the CDAI questionnaire and improvement in
quality of life using the IBDQ after 6 months.
50.7.1.2.3 The Qingdao study (NCT01221428)
This phase I–II study aims to determine the safety and efﬁcacy of
UCMSCs in refractory UC. First, 2× 107 MSCs are injected
intravenously followed 1 week later by 1× 107 MSCs injected
into the mesenteric artery. Outcomes evaluated after 3 months
are improvement in endoscopy ﬁndings and histology and
amelioration of clinical symptoms.
50.7.1.2.4 The La Paz study (NCT01914887)
In this phase I–II study, patients with left-sided colitis and
moderate activity as assessed using a modiﬁed Truelove–Witts
score between 11 and 21, who did not respond to 4 weeks of
treatment with oral and/or topical 5-aminosalicylates, receive
multiple endoscopic injections of allogeneic ASCs into the
affected colonic submucosa at a total dose of 6× 107MSCs. Safety
and efﬁcacy assessed by the modiﬁed Truelove–Witts score,
IBDQ, Mayo endoscopic index, CRP, and fecal calprotectin are
evaluated atweeks 0, 4, 8, and 12. The study is currently recruiting.
50.7.1.2.5 The Washington study (NCT02150551)
In this phase I trial, pediatric patients with IBDs will be random­
ized into three dose groups and will receive eight weekly infu­
sions of allogeneic BM-MSCs. Safety and efﬁcacy will be assessed
using the pediatric CDAI or Pediatric Ulcerative Colitis Activity
Index questionnaires, quality of life using the Impact III IBD
questionnaire, laboratory tests, includingCRP, fecal calprotectin,
and proinﬂammatory cytokines, as well as endoscopic healing
evaluated at day 24 and day 77.
50.8 Issues to be resolved
50.8.1 Source of mesenchymal stromal cells
Most of the published human trials in people with CD have used
ASCs. Only Ciccocioppo et al. used BM-MSCs [229]. ASCs have
the advantage of being easily accessible in large numbers. MSC
treatment requires a large number of cells, and, although MSCs
have great proliferation potential, extended ex vivo expansion
can alter their properties, resulting in reduced differentiation
potential and senescence from the sixth passage onward [234].
Alternatively, expanded ASCs could be superior to nonex­
panded ASCs, known as the stromal vascular fraction, for the
treatment of enterocutaneous ﬁstula in CD, as shown by García-
Olmo et al. in eight patients: three of four ﬁstulas healed in the
ASC group compared to one of four in the stromal vascular
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fraction group [235]. We lack information on differences on
immunophenotype, differentiation potential, transcriptome, and
proteome between BM-MSCs and ASCs. In vitro studies suggest
thatASCsmight be superior toBM-MSCs in suppressing immune
responses [236,237]. In practice, both types of cells have demon­
strated some efﬁcacy, but formal studies comparing the efﬁcacy of
BM-MSCs and ASCs will be needed to resolve this question.
50.8.2 Autologous versus allogeneic
mesenchymal stromal cells
The use of autologous MSCs has raised a debate on whether MSCs
are affected by, ormay contribute to, CD.MSCs from patients with
other autoimmune diseases, such as SLE, have lower proliferation
capacities [238], and the results in human studies on SLE were
disappointing when autologousMSCs were used. However, several
in vitro studies have demonstrated that MSCs from patients with
CDhave similar growth potential andT cell suppression properties
to MSCs from healthy donors [231,239]. Moreover, both autolo­
gous and allogeneicMSCs seempromising inhuman trials,with the
exception of a trial using autologous MSCs in SLE.
50.8.3 Dosage and modalities of administration
Because of the extent and dissemination of luminal lesions in CD,
systemic administration seems required. Inmice, intravenous and
intraperitoneal routes of administration have been used with
equal success, apart from a few studies in which MSCs did not
appear to home to inﬂamed intestine [196,218]. In humans,
intravenous infusion of cells is simple, minimally invasive, rou­
tinely performed, and safe. However, little is known about the
optimal amount of MSCs and the proportion of MSCs that will
reach an inﬂamed intestine. Duijvestein et al. used 1–2× 106
autologousMSCs/kg body without much success [231], while
Onken et al. observed no signiﬁcant difference between low
(2× 106MSCs/kg) and high (8× 106MSCs/kg) [232]. Adminis­
tration of MSCs via selective mesenteric artery cannulation has
been successfully performed in one patient, without any compli­
cation [240]. This route of administration may increase the
number of MSCs reaching the inﬂamed organ, but its superiority
over the intravenous administration is yet to be demonstrated.
Local injection of MSCs has been successfully used in several
studies to treat CD ﬁstulas. In studies showing efﬁcacy of intra­
ﬁstular injections, 10–60× 106 MSCs were injected into each
ﬁstulous tract, and these injections were sometimes repeated.
Ongoing trials are testing higher systemic doses: the Mesoblast
international studies are testing the injection of 6× 108 or
1.2× 109 cells four times over a 2-week period. Several local
dose-escalation trials are also currently ongoing.
50.8.4 Concomitant use of other drugs
MSCs are used concomitantly with immunosuppressive drugs,
and, as they have common targets, it is important to know if the
drugs can affect MSC function. MSCs exposed to physiological
concentrations of azathioprine, methotrexate, 6-mercapto­
purine, and anti-TNF-α antibodies had normal survival and
inhibitory capacities on PBMCproliferationwhen tested in vitro.
An additive effect could even exist with 6-mercaptopurine and
anti-TNF-α antibodies [241].
50.9 Safety
So far there have been no reports of any serious adverse events or
ectopic tissue growth in clinical trials using MSC-based therapy
for CD, nor for graft-versus-host disease [242–244], solid-organ
transplantation [245], cartilage disorders [246], or in many
completed clinical trials for a variety of applications [247,248].
In some studies there was a mild and transient fever shortly after
the time of administration, and this association was found to be
statistically signiﬁcant in a meta-analysis [248]. More experience
is needed in order to conﬁrm the long-term safety of MSCs.
The immunosuppressive properties of MSCs could theoreti­
cally increase susceptibility to infections and cancers. However,
no infections or malignant diseases have been reported as serious
adverse events in MSC-treated CD patients, and there is no
evidence of any increased risk in other applications [248]. In
the context of solid organ transplantation with MSC-based
immunosuppression, one group has even observed a decreased
infection risk compared with standard immunosuppressive
drugs [245]. Another reason for concern for an increased risk
of malignant disease is the need to expandMSCs in vitro in order
to obtain a sufﬁcient number of cells for MSC-based therapy.
While murineMSCs have shown a potential for the development
of chromosomal aberrations and tumor generation after long-
term in vitro culture [249,250], humanMSCs have not shown any
of these risks so far [251–253].Moreover, IBDs are associatedwith
a higher risk of developing colorectal cancer. In amurinemodel of
colitis-associated tumorigenesis induced by azoxymethane and
DSS, MSC-treated animals showed a signiﬁcant reduction in
tumor number and tumor load compared with control mice,
while tumor size remained comparable. This could be linked to a
decreased expression of proinﬂammatory cytokines and down-
regulation of STAT3 phosphorylation [254].
Finally, the effects of MSCs on preexisting cancers have also
been studied. In animal studies some authors found that MSCs
could promote tumor growth [255,256], while others observed a
tumor-suppressive activity of MSCs [257–259]. This dual effect
could be explained by a context-dependent role of MSCs in
regulating tumor growth [260,261]. In a small human trial of
25 patients, co-transplantation of MSCs and HSCs was associ­
ated with a higher relapse rate compared with control patients
(60% versus 20%). However, this observation has not been
conﬁrmed by other studies [262].
50.10 Conclusions
MSCs represent a promising therapy for IBD, especially for CD.
They probably exert their effects through a combination of
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immunomodulation, myogenic differentiation, and the promo­
tion of epithelial repair. Both local injection of MSCs for ﬁstul­
izing CD and intravenous injection of MSCs for luminal IBD
have shown interesting results in several human trials. Unlike
current surgical strategies, MSC administration is a minimally
invasive procedure, which does not injure the anal sphincter and
even promotes a nonﬁbrotic reparative process of ﬁstulas, with
no cases of incontinence reported after MSC treatment. MSCs
seem superior to conventional drugs in term of side effects,
such as opportunist infections. There are still many questions to
answer concerning the optimal source ofMSCs, as well as dosage
and routes of administration.
The efﬁcacy of MSCs compared with conventional treatments
still needs to be demonstrated in randomized controlled trials,
several studies of which are ongoing. They will also likely help us
in the understanding and use of MSCs to treat IBDs.
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